Neuromeka (348340), a South Korean collaborative robot maker on KOSDAQ, announced a simultaneous rights offering and bonus share issuance on April 24, 2026. The company plans to raise approximately 150 billion KRW (~USD 108M) through a shareholder-allotment rights offering, issuing 2,982,109 new shares at a planned price of 50,300 KRW per share.
Why this matters for investors
The fundraising scale is striking: 150 billion KRW represents 46% of Neuromeka's current market cap (~330 billion KRW), and roughly 8x its annual revenue (~19 billion KRW in 2025). Fund allocation: 53% capex, 40% operating capital, 7% debt repayment.
At the same time, the company is offering a bonus share issuance of 0.5 shares per share (post-rights offering), totaling 7,672,130 new shares — a tactic to soften shareholder sentiment while the rights offering dilutes existing stakes by ~24%.
Peer comparison
Neuromeka's market cap (~330B KRW) lags peers Rainbow Robotics (~6.86T KRW) and Doosan Robotics (~4.78T KRW) by 20x, driven by the absence of a large conglomerate backing.
Investor takeaway
Three options for existing shareholders: (1) Participate in the rights offering and receive bonus shares, (2) Skip and absorb ~24% dilution, or (3) Exit before the overhang peaks and re-enter post-listing (August 14, 2026). Key date: July 16, 2026 — final offering price confirmation.
For the full analysis in Korean, visit Snakestock
Top comments (0)